Activ Surgical

Activ Surgical is a pioneering digital surgery company aiming to transform the surgical experience through emerging technologies like augmented reality, artificial intelligence, and machine learning. Their first commercial product is ActivSight, an intelligent light module that seamlessly attaches to existing laparoscopic and robotic surgical systems.

ActivSight provides enhanced visualization capabilities through augmented reality overlays, allowing surgeons to view critical physiological data like tissue perfusion and anatomy in real-time without using fluorescent dyes. It received FDA 510(k) clearance in April 2021 after successful first-in-human studies, and obtained CE Mark approval for the European Union in December 2022.

The core technology powering ActivSight is the ActivEdge platform - designed to leverage AI/ML models trained on large surgical datasets to generate intelligent intraoperative insights. In January 2023, ActivSight's proprietary colorectal AI mode was first utilized by Dr. Matthew Kalady at The Ohio State University Wexner Medical Center, clearly delineating blood perfusion in the colon during a laparoscopic colectomy.

By December 2023, ActivSight had been adopted by multiple major US hospital networks. The first international procedure with the system was performed in December 2023 by Dr. Mohamad Abu-Nuwar at Abdali Hospital in Jordan during a bariatric revision surgery, leveraging the ActivPerfusion mode.

Key customers and partnerships

Activ Surgical has partnered with global technology leaders to optimize their cutting-edge data storage, integration and inference pipelines. The company has raised over USD 120 million from investors including Cota Capital, BAM Funds, Hikma Ventures, NVIDIA and Sony Innovation Fund. Hikma Ventures, the strategic venture arm of Hikma Pharmaceuticals, led Activ Surgical's Series B extension in March 2022 to support international expansion.